Idiopathic- and scleroderma-related pulmonary arterial hypertension: Outcomes and QOL on bosentan

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 4, Issue 5, 2004, Pages 505-513

  Keogh, Anne ^a   Wlodarczyk, John ^b  

^a ST VINCENT S HOSPITAL   (Australia)

^b Biostatistics Consulting Services   (Australia)

Author keywords

Bosentan; Outcomes; Pulmonary arterial hypertension; Quality of life

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ARGININE; BONE MORPHOGENETIC PROTEIN 2; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; NITRIC OXIDE; OXYGEN; PROSTACYCLIN; SILDENAFIL; SPIRONOLACTONE; UNIPROST; WARFARIN;

CLINICAL FEATURE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG USE; FREQUENCY ANALYSIS; HEALTH CARE ACCESS; HEALTH ECONOMICS; HUMAN; IDIOPATHIC DISEASE; INCIDENCE; LIVER DYSFUNCTION; LUNG TRANSPLANTATION; OUTCOMES RESEARCH; OXYGEN THERAPY; PATHOPHYSIOLOGY; PATIENT ATTITUDE; PHYSICAL ACTIVITY; PROGNOSIS; PULMONARY HYPERTENSION; QUALITY OF LIFE; RARE DISEASE; REVIEW; SCLERODERMA; SOCIAL INTERACTION; SURVIVAL RATE;

EID: 5444259382     PISSN: 14737167     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737167.4.5.505     Document Type: Review

References (52)

1. Channick RN, Simonneau G, Sitbon O et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358, 1119-1123 (2001).
2. Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 346, 896-903 (2002).
3. Keogh A, Macdonald P, Williams T et al. Tracleer® (Bosentan) for the treatment of pulmonary arterial hypertension (PAH)-6 month quality of life data. Heart Lung & Circulation (2004) (In Press).
4. McLaughlin V, Sitbon O, Rubin LJ et al. The effects of first-line bosentan on survival of patients with primary pulmonary hypertension. Am. J. Resp. Crit. Care Med. 167, 442 (2003).
5. Galiè N, Hinderliter AL, Torbicki A et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension. J. Am. Coll. Cardiol. 41, 1380-1386 (2003).
6. Owens DK. Interpretation of cost-effectiveness analyses. J. Gen. Intern. Med. 13(10), 716-717 (1998).
7. Towse A. What is NICE's threshold? An external view. In: Cost Effectiveness Thresholds: Economic and Ethical Issues. Devlin N,Towse A (Eds). Kings Fund/Office for Health Economics, London, UK (2002).
8. George B, Harris A, Mitchell A. Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996). PharmacoEconomics 19(11), 1103-1109 (2001).
9. Koh ET, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br. J. Rheum. 35, 989-993 (1996).
10. MacGregor AJ, Canavan R, Knight C et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumotology 40, 453-459 (2001).
11. Galiè N, Manes A, Uguccioni L et al. Primary pulmonary hypertension; insights into the pathogenesis from epidemiology. Chest 114, S184-S194 (1998).
12. Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet 352, 719-725 (1998).
13. British Cardiac Society Guidelines. Recommendations on the management of pulmonary hypertension in clinical practice. Heart 86(Supp. I), I1-I13 (2001).
14. Keogh AM, McNeil KD, Williams T, Gabbay E, Cleland LG. Pulmonary arterial hypertension: a new era in management. Med. J. Aust. 178, 564-567 (2003).
15. Fowler N, Wescott R, Scott R. Normal pressure in right heart and pulmonary artery. Am. Heart J. 46, 264-270 (1953).
16. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 70(4), 580-587 (1984).
17. Kim NHS, Rubin LJ. Endothelin in Health and disease: endothelin receptor antagonists in the management of pulmonary artery hypertension. J. Cardiovasc. Pharmacol. Therapeut. 7(1), 9-19 (2002).
18. Hoeper MM, Galiè N, Simonneau G, Rubin LJ. New treatments for pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 165, 1209-1216 (2002).
19. Yanagisawa M, Kurihara H, Kimura S et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332, 411-415 (1988).
20. Roux S, Breu V, Ertel SI, Clozel M. Endothelin antagonism with bosentan: a review of potential applications. J. Mol. Med. 77, 364-376 (1999).
21. Rubin LJ, Roux S. Bosentan: a dual endothelin receptor antagonist. Expert. Opin. Investig. Drugs 11(7), 991-1002 (2002).
22. Krum H, Liew D. Current status of endothelin blockade for the treatment of cardiovascular and pulmonary vascular disease. Curr. Opin. Investig. Drugs 4(3), 298-302 (2003).
23. Lane K, Machado R, Pauciulo M et al. Heterozygous germline mutations in BMPR2, encoding a TGF-B receptor, cause familial primary pulmonary hypertension. Nature Genetics 26, 81-84 (2000).
24. D'Alonzo G, Barst R, Ayres S et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann. Intern. Med. 115(5), 343-349 (1991).
25. Nagaya N, Nishikimi T, Venetsu M et al. Plasma brain naturetic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 102, 865-870 (2000).
26. Miyamoto S, Nagaya N, Satoh T et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Am. J. Respir. Crit. Care Med. 161, 487-492 (2000).
27. Chua R, O'Loughlin A, Keogh A, Brown K, Corrigan C. Comparison and validation of three quality of life instruments for the functional assessment of pulmonary arterial hypertension. J. Heart Lung Transplant. 23, 5143 (2004).
28. Gabbay E, McNeil K, William T, Wlodarczyk J, Seale H, Keogh A. Tracleer® (bosentan) therapy in patients with pulmonary arterial hypertension: the relationship between improvements in six-minute walk test (6MWT) and quality of life (QOL). American Thoracic Society 100th International Conference. FL, USA, (2004).
29. Wight JP, Edwards L, Brazier J, Waters S, Payne JN, Brown CB. The SF-36 as an outcome measure of services for end stage renal failure. Qual. Healthcare 7(4), 209-221 (1998).
30. Harper R, Brazier JE, Waterhouse JC, Walters SJ, Jones NM, Howard P. Comparison of outcome measures for patients with chronic obstructive pulmonary disease (COPD) in an outpatient setting. Thorax 52(10), 879-887 (1997).
31. Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomised, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. Am. Heart J. 124(4), 1017-1025 (1992).
32. McKenna S, Doughty N, Pepke-Zaba J. Qualitative patient interviews demonstrate the need to develop quality of life (QOL) and health-related quality of life (HRQL) measures specific to pulmonary arterial hypertension. PAH Symposium JACC 2003 (2004) (In Press).
33. Rich S, Brundage B, Levy P. The effect of vasodilator therapy on the clinical outcome of patients with primary pulmonary hypertension. Circulation 71(6), 1191-1196 (1985).
34. Sitbon O, Humbert M, Ioos V et al. Who benefit from long-term calcium-channel blocker (CCB) therapy in primary pulmonary hypertension (PPH). American Thoracic Society 99th International Conference. WA, USA, A440 (2003).
35. Barst RJ, Rubin LJ, Long WA et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N. Engl. J. Med. 334(5), 296-302 (1996).
36. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 106(12), 1477-1482 (2002).
37. Sitbon O, Humbert M, Nunes H et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J. Am. Coll. Cardiol. 40(4), 780-788 (2002).
38. Hoeper M, Schwaze M, Ehlerding S et al. Long-term treatment of primary pulmonary hypertension with aerosolised iloprost, a prostacyclin analogue. N. Engl. J. Med. 342, 1866-1870 (2000).
39. Galiè N, Humbert M, Vachiery J-L et al. Effects of beraprost sodium an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomised, double-blind placebo-controlled trial. J. Am. Coll. Cardiol. 39, 1496-1502 (2002).
40. Olschewski H, Simmonneau G, Galiè N et al. Inhaled iloprost for severe pulmonary hypertension. N. Engl. J. Med. 347(5), 322-329 (2002).
41. Sastry BK, Narasimhan C, Reddy NK et al. A study of clinical efficacy of sildenafil in patients with primary pulmonary hypertension. Indian Heart J. 54(4), 410-414 (2002).
42. Humbert M, Simmonneau S. Sildenafil for pulmonary arterial hypertension. Still waiting for evidence. Am. J. Resp. Crit. Care Med. 169, 6-7 (2004).
43. Cooper DA, Macdonald PS, Sitbon O et al. Bosentan treatment in patients with pulmonary arterial hypertension associated with HIV infection. 15th Annual Conference of the Australasian Society for HIV Medicine (ASHM). Cairns, Australia (2003).
44. Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. Circulation 99, 1197-1208 (1999).
45. Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 123, 344-350 (2003).
46. Bedi M, Spates-Panyon J, Mathier M et al. Long-term survival comparison in patients with primary and secondary pulmonary arterial hypertension treated with chronic epoprostenol therapy. 52nd Annual Scientific Conference of the American College of Cardiology. Chicago, USA (2003).
47. Policy Analysis, Inc. Exploratory Analyses of Data from BREATHE-1 on Measures of Potential Pharmacoeconomic Significance. Brookline, Mass. (2001).
48. Highland K, Strange C, Mazur J, Simpson K. Treatment of pulmonary arterial hypertension: a preliminary decision analysis. Chest 124, 2087-2092 (2003).
49. Keogh A, Brown K, Corrigan C, Allada C, Ten Y. The effect of open-label UT15 and bosentan on hospitalisation rate in patients with pulmonary arterial hypertension. J. Heart Lung Transplant. 21, 159 (2002).
50. Humbert M, Barst RJ, Robbins IM et al. Safety & efficacy of bosentan combined with epoprostenol in patients with severe pulmonary arterial hypertension. American Thoracic Society 99th International Conference. Seattle USA, A441 (2003).
51. Barst RJ, Ivy D, Dingemanse J et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin. Pharmacol. Ther. 73(4), 372-382 (2003).
52. Hopman WM, Towheed T, Anastassiades T et al. Canadian normative data for the SF-36 health survey. Canadian Multicentre Osteoporosis Study Research Group. CMAJ 163(3), 265-271 (2000).